Search Results
Global SYMPLICITY Registry (GSR) Denervation Findings in Real World (DEFINE)- US Cohort is referred to as the GSR DEFINE- US Cohort study
A PROSPECTIVE, OBSERVATIONAL STUDY THAT WILL DOCUMENT THE LONG-TERM SAFETY, EFFECTIVENESS, AND DURABILITY OF RENAL DENERVATION IN A REAL-WORLD POPULATION, AGED 65 YEARS OR GREATER WITH HYPERTENSION IN THE UNITED STATES.
Sarah Ackroyd - sackroy1@hfhs.org
HEART Camp Connect - R01
This study aims to promote long-term adherence to exercise in adults with heart failure with preserved ejection fraction (HFpEF) by providing an exercise coach for up to one year. We will test a virtual group and in-person group against each other and against virtual enhanced usual care.
Crystal Grimshaw - cgrimsh1@hfhs.org
• diagnosis heart failure with EF >50%
• age >19 years old
• Echocardiogram within past 24 months
• chest pain
• heart attack, coronary artery bypass surgery, or pacemaker implant within past 6 weeks
• ICD (defibrillator)
The Fourth Left Atrial Appendage Occlusion Study: (LAAOS-4)
The purpose of the LAAOS-4 study is to determine if closure of the left atrial appendage using a closure device called the WATCHMAN?, in addition to taking oral anticoagulant medications, is more effective at reducing strokes and blood clots in your body, than taking oral anticoagulant medications on their own.
Briita Wanhala - bwanhal1@hfhs.org
• Adults, 18 years or older
• Have long-term atrial fibrillation (persistent or permanent) OR paroxysmal atrial fibrillation with a history of stroke or blood clots
• Taking an oral anticoagulant
• Unable to tolerate oral anticoagulants
• Prior closure of the left atrial appendage
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants with Elevated Lipoprotein(a)
This research study is testing whether an investigational medication called olpasiran can help prevent serious heart and blood vessel problems, such as a heart attack or stroke, in people who have high levels of a substance in their blood called lipoprotein(a), or Lp(a), and who are at increased risk of having a cardiac event.
Jodi Carter - GeneralCardiologyResearch@hfhs.org
• Age 50 or greater
• Lp(a) greater than or equal to 200 nmol/L
• Prior arterial revascularization
• Severe kidney dysfunction
• Severe liver dysfunction
A Phase 3, Randomized, Multicenter, Double-Blind, PlaceboControlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)
ACT-EARLY is a research study to see if an investigational drug, acoramidis (AG10), is safe and effective in preventing or delaying symptoms of a disease called Transthyretin Amyloidosis (ATTR).This research study will test whether acoramidis treatment in people who do not have the disease but who carry a genetic predisposition to developing the disease is safe and effective in preventing or delaying ATTR disease (genetic predisposition is also referred to as genetic variant).
Kristin Clark - kclark2@hfhs.org